Imiquimod 5% cream: a new treatment option for basal cell carcinoma

Salasche, Stuart J.

doi:10.1111/j.1365-4632.2002.00020.x

Cited by 11 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two varieties of BCC account for the majority of tumors: nodular BCCs (nBCC) and superficial BCCs (sBCC), 36 with imiquimod being indicated for the treatment of sBCC.…”

Section: Supercial Basal Cell Carcinoma (Sbcc)mentioning

confidence: 99%

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

“…Two varieties of BCC account for the majority of tumors: nodular BCCs (nBCC) and superficial BCCs (sBCC), 36 with imiquimod being indicated for the treatment of sBCC.…”

Section: Supercial Basal Cell Carcinoma (Sbcc)mentioning

confidence: 99%

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

“…It thus promotes tumor surveillance. [29] Others[30] have suggested that tumor regression is achieved probably by induction of Fas receptors on the tumor cells, resulting in their apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Periungual basal cell carcinoma: A case report with review of literature

Bandyopadhyay

Sen

2011

Indian J Dermatol

View full text Add to dashboard Cite

Basal cell carcinomas (BCCs) are considered to be uncommon around the nail plate. An indolent lesion of this region should arouse suspicion of potential malignancy and a skin biopsy should be undertaken without delay. Early diagnosis can enable the physician to render simpler nondestructive modalities of treatment. In this article, we describe such a case of longstanding BCC of this region mimicking a traumatic ulcer. The nature of the ailment was finally discovered on biopsy and the carcinoma was initially treated with topical Imiquimod.

show abstract

“…The efficacy of imiquimod approaches that of surgical or ablative modalities; however, these are often painful, and may, depending on site, leave unsightly scarring. Imiquimod is a patient‐applied treatment option, which results in good cosmetic outcome 11–13 …”

Section: Discussionmentioning

confidence: 99%

Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients

Bianchi

Costanzo

Campione

et al. 2003

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Skin cancer is the most common malignancy in humans and accounts for one-third of newly diagnosed cancers. Basal cell carcinoma (BCC) is one of the most prevalent and persistent types, and appears in two main histological forms, superficial and nodular. Typical treatments include surgery; however, this may leave scarring, which is undesirable, especially in facial lesions. We report the results of seven individual patients with one or more BCCs (both nodular and superficial) treated with imiquimod 5% cream. Eleven of 13 lesions cleared following daily topical treatment for 10-18 weeks. Any local skin reactions resolved at the end of treatment.

show abstract

Imiquimod 5% cream: a new treatment option for basal cell carcinoma

Cited by 11 publications

References 22 publications

Viral and Nonviral Uses of Imiquimod: A Review

Viral and Nonviral Uses of Imiquimod: A Review

Periungual basal cell carcinoma: A case report with review of literature

Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients

Contact Info

Product

Resources

About